Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · NEPHROPLUS

NEPHROPLUS

HealthcareHealthcare Services₹6558 cr market cap
₹641.95 ▼ -1.69% today As of 19 Nov 2026
52-week low ₹449.1552-week high ₹765.35

-14.7% from the 52-week high · +45.4% above the low

Nephrocare Health Services Ltd specializes in renal care and dialysis services. The company operates dialysis centers offering treatment to patients with chronic kidney disease. It follows a standardized care delivery model focused on clinical protocols and patient outcomes. Nephrocare collaborates with hospitals and healthcare institutions to expand access. Its operations are centered on affordable, long-term disease management.

The short version. Return on equity was 6.9% in Mar 2026. Promoter holding was 58.31% in Sep 2026, down 5.54 points over 4 quarters.

1 · The price

How has the stock traded?

NEPHROPLUS trades 14.7% below its 52-week high and 45.4% above its 52-week low.

Change over period: —

1M+6.8%
3M-5.5%
6M+6.3%
1Y—

2 · The business

Is it growing?

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025
Revenue303282266260
Net profit34323032
Net margin %11.111.311.412.4
EPS (₹)3.333.193.033.21

Annual

FY2026
Revenue999
Net profit77
Net margin %7.7
EPS (₹)7.66

3 · The quality

How well does it turn capital into profit?

Return on equity was 6.9% in Mar 2026; debt to equity is 0.07.

Profitability · 1 years

Returns and margins

Mar 2026
Return on equity %6.9
Return on capital %13.7
EBITDA margin %24.6
Net margin %7.5

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR——
Profit CAGR——
Debt to equity0.07
Interest cover2.7x
Current ratio2.80
P/E ratio51.4

4 · The owners

Who holds it, and are they adding?

Promoter holding58.31%

Down 5.54 pts over 4 quarters.

Foreign institutions11.73%

Up 2.43 pts over 4 quarters.

Domestic institutions8.11%

Up 0.01 pts over 4 quarters.

Mutual fund schemes27

+4 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter63.8563.8563.8558.31-5.54
FII9.39.948.7811.73+2.43
DII8.18.659.058.11+0.01
Public18.7417.5618.3221.85+3.11

Mutual fund holdings · Oct 2026

27 schemes hold this stock

23 the month before.

  • LIC MF HEALTHCARE FUND4.14% of NAV
  • LIC MF VALUE FUND4.11% of NAV
  • LIC MF INFRASTRUCTURE FUND2.24% of NAV
  • Baroda BNP Paribas Health and Wellness Fund1.35% of NAV
  • LIC MF MULTI ASSET ALLOCATION FUND1.33% of NAV
  • Helios Small Cap Fund1.24% of NAV
  • DSP Healthcare Fund1.05% of NAV
  • SBI Healthcare Opportunities Fund1.01% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for NEPHROPLUS are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about NEPHROPLUS

What is the NEPHROPLUS share price?

NEPHROPLUS (NEPHROPLUS) last closed at ₹641.95, down 1.69% on the day. Its 52-week range is ₹449.15 to ₹765.35.

What is the market cap of NEPHROPLUS?

NEPHROPLUS has a market capitalisation of about ₹6,558 crore. Its price-to-earnings ratio is 51.4.

How are NEPHROPLUS's latest results?

Return on equity was 6.9% in Mar 2026. Promoter holding was 58.31% in Sep 2026, down 5.54 points over 4 quarters.

Who owns NEPHROPLUS?

As of Sep 2026, shareholding was: Promoter 58.31%, FII 11.73%, DII 8.11%, Public 21.85%.

How many mutual funds hold NEPHROPLUS?

27 mutual fund schemes held NEPHROPLUS in October 2026. That compares with 23 the month before.

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.